Lange Christoph, Wagner Dirk
Forschungszentrum Borstel, Leibniz Lungenzentrum.
Abteilung Infektiologie, Klinik für Innere Medizin II, Universitätsklinikum Freiburg.
Dtsch Med Wochenschr. 2022 Sep;147(17):1114-1121. doi: 10.1055/a-1764-3320. Epub 2022 Aug 28.
The spectrum of pulmonary disease caused by nontuberculous mycobateria (NTM) is diverse, and each species requires species-specific therapy. With the new ATS/ERS/ESCMID/IDSA guideline on the management of pulmonary disease caused by NTMs covering only the most common pathogens, namely M. avium complex (MAC), M. kansasii, M. xenopi, and M. abscessus, it was necessary to write treatment recommendations for pulmonary disease caused by rarer NTM species that were still represented in the old 2007 guideline.The panel of guideline committee members from the ATS, ERS, ESCMID, and IDSA- therefore, independently of the professional societies, again conducted systematic literature reviews to develop evidence-based recommendations for the treatment of lung disease caused by seven additional organisms: M. chelonae, M. fortuitum, M. genavense, M. gordonae, M. malmoense, M. simiae, and M. szulgai. A German summary of these international recommendations is presented here.
非结核分枝杆菌（NTM）引起的肺部疾病谱多种多样，每种菌株都需要特定的治疗方法。新的美国胸科学会（ATS）/欧洲呼吸学会（ERS）/欧洲临床微生物学和传染病学会（ESCMID）/美国感染病学会（IDSA）关于NTM所致肺部疾病管理的指南仅涵盖了最常见的病原体，即鸟分枝杆菌复合群（MAC）、堪萨斯分枝杆菌、蟾分枝杆菌和脓肿分枝杆菌，因此有必要针对2007年旧版指南中仍提及的罕见NTM菌株所致肺部疾病撰写治疗建议。ATS、ERS、ESCMID和IDSA的指南委员会成员小组，因此独立于专业学会，再次进行了系统的文献综述，以制定针对另外七种病原体所致肺部疾病治疗的循证建议，这七种病原体为：龟分枝杆菌、偶然分枝杆菌、日内瓦分枝杆菌、戈登分枝杆菌、马尔默分枝杆菌、猿分枝杆菌和苏尔加分枝杆菌。本文给出了这些国际建议的德文摘要。
